HRCM
ACAD icon

Hood River Capital Management’s Acadia Pharmaceuticals ACAD Stock Holding History

Hood River Capital Management’s Portfolio ACAD Stock Details ACAD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-469,381
Closed -$7.22M – 160
2024
Q3 		$7.22M Buy
+469,381
New +$7.83M 0.12% 108
2023
Q4 		– Sell
-877,827
Closed -$18.3M – 123
2023
Q3 		$18.3M Buy
+877,827
New +$23.8M 0.59% 65
2020
Q4 		– Sell
-422,765
Closed -$17.4M – 106
2020
Q3 		$17.4M Buy
422,765
+121,229
+40% +$5.24M 0.76% 50
2020
Q2 		$14.6M Sell
301,536
-288,828
-49% -$13.9M 0.66% 61
2020
Q1 		$24.9M Buy
+590,364
New +$24.3M 1.43% 20

Other funds holding ACAD

BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return

Hood River Capital Management's ACAD Position: Q4 2024 in Review

Hood River Capital Management sold out of Acadia Pharmaceuticals (ACAD) in Q4 2024, closing a stake of 469,381 shares — an estimated $7.22M sold.

Hood River Capital Management first reported a position in ACAD in Q1 2020 and held it in 5 quarters. The position peaked at $24.9M in Q1 2020. 296 funds tracked by Wall St. Rank hold ACAD as of Q4 2024.

  • Hood River Capital Management reported no remaining Acadia Pharmaceuticals position as of Q4 2024 after selling out during the quarter.
  • Hood River Capital Management sold 469,381 Acadia Pharmaceuticals shares in Q4 2024, an estimated $7.22M.
  • Hood River Capital Management first reported a position in Acadia Pharmaceuticals in Q1 2020 and held it in 5 quarters.
  • Hood River Capital Management's Acadia Pharmaceuticals position peaked at $24.9M in Q1 2020.
  • 296 funds tracked by Wall St. Rank held Acadia Pharmaceuticals as of Q4 2024.

Based on Hood River Capital Management's 13F filing for Q4 2024, filed 14 Feb 2025.